GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism.
- DOI
- 10.1016/j.bneo.2025.100130
- Published
- 2025 Aug
- Container
- Blood neoplasia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bneo.2025.100130,
title = {GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism.},
author = {Li S and Krüger J and Liu G and Ma H and Hughes MS and Chakraborty R and Bhutani D and Mapara MY and Marcireau C and Lentzsch S and Fu J},
year = {2025},
journal = {Blood neoplasia},
doi = {10.1016/j.bneo.2025.100130},
url = {https://doi.org/10.1016/j.bneo.2025.100130}
}RIS
TY - JOUR TI - GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism. AU - Li S AU - Krüger J AU - Liu G AU - Ma H AU - Hughes MS AU - Chakraborty R AU - Bhutani D AU - Mapara MY AU - Marcireau C AU - Lentzsch S AU - Fu J PY - 2025 JO - Blood neoplasia DO - 10.1016/j.bneo.2025.100130 UR - https://doi.org/10.1016/j.bneo.2025.100130 ER -
APA
S, L., J, K., G, L., H, M., MS, H., R, C., D, B., MY, M., C, M., S, L., & J, F. (2025). GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism.. Blood neoplasia. https://doi.org/10.1016/j.bneo.2025.100130
Source records
- pubmed · retrieved 2026-09-26T22:08:45.193Z
- europe-pmc · retrieved 2026-09-26T22:08:45.210Z
- doaj · retrieved 2026-09-26T22:08:45.204Z